Imaging histone deacetylases with a radiotracer using positron emission tomography
US-2016271276-A1 · Sep 22, 2016 · US
HDAC6 inhibitors and imaging agents
US11207431B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11207431-B2 |
| Application number | US-201816603746-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 11, 2018 |
| Priority date | Apr 11, 2017 |
| Publication date | Dec 28, 2021 |
| Grant date | Dec 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, which is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition, comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 3. A method of inhibiting an activity of a histone deacetylase (HDAC) enzyme, comprising contacting the HDAC enzyme with a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 4. The method of claim 3 , wherein the histone deacetylase (HDAC) enzyme is HDAC6. 5. The method of claim 3 , wherein the compound selectively inhibits HDAC6 over one or more of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, and HDAC11. 6. The compound of claim 1 , which is: or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , which is: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07C259/10Primary
having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings · CPC title
the bicyclo ring system containing seven carbon atoms · CPC title
- A61K51/04Primary
Organic compounds · CPC title
Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title
Adamantanes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11207431B2 cover?
- Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.
- Who is the assignee on this patent?
- Massachusetts Gen Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07C259/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).